Meta-analysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric primary treatment of helicobacter pylori infection

Digestion

Volumn 88, Issue 1, 2013, Pages 33-45

  Venerito, Marino ^a   Krieger, Tina ^b   Ecker, Thomas ^b   Leandro, Gioacchino ^c   Malfertheiner, Peter ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b Ecker + Ecker GmbH   (Germany)

^c Gastroenterology Unit 1   (Italy)

Author keywords

Antibiotic resistance; Helicobacter pylori; Quadruple therapy; Triple therapy

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; BISMUTH; BISMUTH CITRATE; CLARITHROMYCIN; METRONIDAZOLE; OMEPRAZOLE; TETRACYCLINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; DRUG EFFICACY; DRUG TOLERABILITY; HELICOBACTER INFECTION; HUMAN; INTENTION TO TREAT ANALYSIS; META ANALYSIS; PATHOGEN CLEARANCE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ANTI-BACTERIAL AGENTS; BISMUTH; CLARITHROMYCIN; DRUG THERAPY, COMBINATION; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; METRONIDAZOLE; PROTON PUMP INHIBITORS; TETRACYCLINE;

EID: 84880296037     PISSN: 00122823     EISSN: 14219867     Source Type: Journal    
DOI: 10.1159/000350719     Document Type: Review

References (34)

1. Nagini S: Carcinoma of the stomach: a review of epidemiology, pathogenesis, molecular genetics and chemoprevention. World J Gastrointest Oncol 2012; 4: 156-169.
2. Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F, et al: Management of Helicobacter pylori infection-the Maastricht IV/Florence Consensus Report. Gut 2012; 61: 646-664.
3. Glupczynski Y, Megraud F, Lopez-Brea M, Andersen LP: European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori. Eur J Clin Microbiol Infect Dis 2001; 20: 820-823.
4. Megraud F, Coenen S, Versporten A, Kist M, Lopez-Brea M, Hirschl AM, et al: Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 2013; 62: 34-42.
5. Gene E, Calvet X, Azagra R, Gisbert JP: Triple vs. quadruple therapy for treating Helicobacter pylori infection: a meta-analysis. Aliment Pharmacol Ther 2003; 17: 1137-1143.
6. Luther J, Higgins PD, Schoenfeld PS, Moayyedi P, Vakil N, Chey WD: Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: systematic review and meta-analysis of efficacy and tolerability. Am J Gastroenterol 2010; 105: 65-73.
7. Leandro G: Meta-Analysis in Medical Research: The Handbook for the Understanding and Practice of Meta-Analysis (with software). Malden, BMJ Books, 2005.
8. Gomollon F, Valdeperez J, Garuz R, Fuentes J, Barrera F, Malo J, et al: Cost-effectiveness analysis of 2 strategies of Helicobacter pylori eradication: results of a prospective and randomized study in primary care. Medicina Clinica 2000; 115: 1-6.
9. Calvet X, Ducons J, Guardiola J, Tito L, Andreu V, Bory F, et al: One-week triple vs. quadruple therapy for Helicobacter pylori infection-a randomized trial. Aliment Pharmacol Ther 2002; 16: 1261-1267.
10. Katelaris PH, Forbes GM, Talley NJ, Crotty B: A randomized comparison of quadruple and triple therapies for Helicobacter pylori eradication: The QUADRATE Study. Gastroenterology 2002; 123: 1763-1769.
11. Mantzaris GJ, Petraki K, Archavlis E, Amberiadis P, Christoforidis P, Kourtessas D, et al: Omeprazole triple therapy versus omeprazole quadruple therapy for healing duodenal ulcer and eradication of Helicobacter pylori infection: a 24-month follow-up study. Eur J Gastroenterol Hepatol 2002; 14: 1237-1243.
12. Laine L, Hunt R, El-Zimaity H, Nguyen B, Osato M, Spenard J: Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial. Am J Gastroenterol 2003; 98: 562-567.
13. Pai CG, Thomas CP, Biswas A, Rao S, Ramnarayan K: Quadruple therapy for initial eradication of Helicobacter pylori in peptic ulcer: comparison with triple therapy. Indian J Gastroenterol 2003; 22: 85-87.
14. Jang HJ, Choi MH, Kim YS, Seo YA, Baik KH, Baik IH, et al: Effectiveness of triple therapy and quadruple therapy for Helicobacter pylori eradication (in Korean). Korean J Gastroenterol 2005; 46: 368-372.
15. Uygun A, Kadayifci A, Safali M, Ilgan S, Bagci S: The efficacy of bismuth containing quadruple therapy as a first-line treatment option for Helicobacter pylori. J Dig Dis 2007; 8: 211-215.
16. Ching SS, Sabanathan S, Jenkinson LR: Treatment of Helicobacter pylori in surgical practice: a randomised trial of triple versus quadruple therapy in a rural district general hospital. World J Gastroenterol 2008; 14: 3855-3860.
17. Songür Y, Senol A, Balkarli A, Basturk A, Cerci S: Triple or quadruple tetracycline-based therapies versus standard triple treatment for Helicobacter pylori treatment. Am J Med Sci 2009; 338: 50-53.
18. Zheng Q, Chen WJ, Lu H, Sun QJ, Xiao SD: Comparison of the efficacy of triple versus quadruple therapy on the eradication of Helicobacter pylori and antibiotic resistance. J Dig Dis 2010; 11: 313-318.
19. Malfertheiner P, Bazzoli F, Delchier JC, Celinski K, Giguere M, Riviere M, et al: Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, noninferiority, phase 3 trial. Lancet 2011; 377: 905-913.
20. Singh V, Mishra S, Maurya P, Rao G, Jain AK, Dixit VK, et al: Drug resistance pattern and clonality in H. pylori strains. J Infect Dev Ctries, 2009; 3: 130-136.
21. Chung JW, Lee GH, Jeong JY, Lee SM, Jung JH, Choi KD, et al: Resistance of Helicobacter pylori strains to antibiotics in Korea with a focus on fluoroquinolone resistance. J Gastroenterol Hepatol 2012; 27: 493-497.
22. Onder G, Aydin A, Akarca U, Tekin F, Ozutemiz O, Ilter T: High Helicobacter pylori resistance rate to clarithromycin in Turkey. J Clin Gastroenterol 2007; 41: 747-750.
23. Fuccio L, Minardi ME, Zagari RM, Grilli D, Magrini N, Bazzoli F: Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication. Ann Intern Med 2007; 147: 553-562.
24. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al: Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12.
25. Zagari RM, Bianchi-Porro G, Fiocca R, Gasbarrini G, Roda E, Bazzoli F: Comparison of 1 and 2 weeks of omeprazole, amoxicillin and clarithromycin treatment for Helicobacter pylori eradication: the HYPER Study. Gut 2007; 56: 475-479.
26. Rimbara E, Fischbach LA, Graham DY: Optimal therapy for Helicobacter pylori infections. Nat Rev Gastroenterol Hepatol 2011; 8: 79-88.
27. Chey WD, Wong BC: American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007; 102: 1808-1825.
28. Fock KM, Katelaris P, Sugano K, Ang TL, Hunt R, Talley NJ, et al: Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol 2009; 24: 1587-1600.
29. Asaka M, Kato M, Takahashi S, Fukuda Y, Sugiyama T, Ota H, et al: Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised edition. Helicobacter 2010; 15: 1-20.
30. de Boer WA: Bismuth triple therapy: still a very important drug regimen for curing Helicobacter pylori infection. Eur J Gastroenterol Hepatol 1999; 11: 697-700.
31. van der Wouden EJ, Thijs JC, van Zwet AA, Sluiter WJ, Kleibeuker JH: The influence of in vitro nitroimidazole resistance on the efficacy of nitroimidazole-containing anti-Helicobacter pylori regimens: a meta-analysis. Am J Gastroenterol 1999; 94: 1751-1759.
32. Graham DY, Fischbach L: Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 2010; 59: 1143-1153.
33. Megraud F, Broutet N: Epidemiologie des maladies infectieuses en France en 1997. Surveillance de la resistance aux antibiotiques. Bull Epidemiol Ann 1999: 187-188.
34. Salazar CO, Cardenas VM, Reddy RK, Dominguez DC, Snyder LK, Graham DY: Greater than 95% success with 14-day bismuth quadruple anti-Helicobacter pylori therapy: a pilot study in US Hispanics. Helicobacter 2012; 17: 382-390.